Jun 20, 2024 8:30am EDT Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
Jun 13, 2024 8:00am EDT Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain